^
Association details:
| Biomarker: | KRAS G12C + SMARCA4 wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | KRAS inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1060P - Impact of baseline clinicopathologic and genomic features on outcomes to KRAS G12C inhibitors in patients with NSCLC
Published date:
09/05/2022
Excerpt:
Ninety-two pts received a G12Ci (median age 66.5 years, 63% female)...the ORR was 39% (N=31/80), the median PFS (mPFS) was 5.1 months, and the median OS (mOS) was 9.8 months….ATM wild-type (wt) compared to ATM mut had lower ORR (33% vs 78%, p=0.02) and shorter mPFS (4.1 vs 13.8 months, p=0.04)....Longer mPFS and mOS were observed in SMARCA4 wt compared to mut (mPFS: 5.9 vs 2.8 months, p=0.02; mOS: 11.3 vs 5.3 months, p=0.02)....Baseline clinicopathological characteristics may help predict outcome to G12Ci in pts with KRASG12C-mutant NSCLC.
